What Gattaca Genomics does

Gattaca Genomics is a Fort Lauderdale, Florida-based clinical laboratory that provides preimplantation genetic testing (PGT) and genetic counseling services for the IVF market. Its core offerings comprise three PGT modalities — PGT-A for aneuploidy screening, PGT-M for monogenic disorder detection, and PGT-SR for chromosomal structural rearrangement analysis — supplemented by board-certified genetic counselors who deliver pre- and post-test consultations to fertility patients and clinicians.

Operationally, Gattaca runs a B2B2C service model: embryo cells are collected at partner IVF clinics and fertility centers, transported to Gattaca's laboratory for next-generation sequencing analysis, and detailed reports are returned to the referring physician and patient. The lab is CLIA-certified and HIPAA-compliant, satisfying federal clinical-laboratory and patient-data requirements. Pricing is not publicly disclosed and appears to be quote-based given the specialized clinical nature of genetic testing. Marketing is concentrated on the company's own website with video content and direct "Get Started" calls-to-action targeting both enterprise clinic buyers and individual patients.

The company's principal technological differentiator is a deep learning-based embryo selection system that has received clinical trial approval, positioned by the company as a landmark AI-enhanced approach to embryo ranking. Gattaca maintains technology/vendor relationships with major life-sciences suppliers — ThermoFisher Scientific, Element Bioscience, Genea, VitroLife, and ArtLab — and aligns with the American Society for Reproductive Medicine (ASRM), anchoring its credibility and laboratory stack within the reproductive-medicine ecosystem.

Name

Gattaca Genomics

Legal name

Gattaca Genomics

Website

https://gattacagenomics.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Gattaca Genomics is a Fort Lauderdale-based CLIA-certified laboratory providing preimplantation genetic testing (PGT-A, PGT-M, PGT-SR) and genetic counseling for IVF clinics and fertility patients, with a deep learning embryo selection system in clinical trials.

Ownership category

akta.pro rank

Product category

Reproductive Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI), Molecular Cytogenetics & Genomic Variation Services (Karyotyping/FISH/aCGH/CNV) (HLAGANAJ)

Keywords

• Preimplantation genetic testing
• IVF genetic screening
• Embryo selection services
• Reproductive genetic counseling
• PGT laboratory services

Headquarters

HQ city

Fort Lauderdale

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Genetic Testing Services: Laboratory-based genetic analysis services for embryos, involving sample collection at IVF centers, transport to Gattaca's lab, analysis using next-generation sequencing, and delivery of detailed reports to physicians and patients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Gattaca Genomics is a CLIA-certified clinical laboratory providing Preimplantation Genetic Testing (PGT) for IVF centers and fertility patients. Services include PGT-A (aneuploidy screening), PGT-M (monogenic disorder testing), and PGT-SR (chromosomal structural rearrangement testing), supported by board-certified genetic counseling. The company also operates a deep learning-enhanced embryo selection program that has been approved for clinical trials.

Product overview

Gattaca Genomics offers a unified genetic testing platform centered on Preimplantation Genetic Testing (PGT) services designed for IVF centers and fertility patients. The core offering consists of three PGT modalities: PGT-A for aneuploidy screening, PGT-M for monogenic disorder detection, and PGT-SR for chromosomal rearrangement analysis. These services are complemented by expert genetic counseling to guide patients through the testing process. The company is also advancing into AI-powered embryo selection using deep learning, which has received approval for clinical trials, representing a significant technological enhancement to their testing portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Preimplantation Genetic Testing for Aneuploidy (PGT-A) Genetic screening test that detects aneuploidy (abnormal chromosome numbers) in embryos to help identify embryos with the highest potential for successful pregnancy transfer. Sold to IVF clinics and fertility specialists for use with their fertility patients.
• Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) Genetic testing that identifies single-gene disorders (such as cystic fibrosis or Huntington's disease) in embryos, allowing parents with known genetic conditions to make informed family planning decisions. Sold to IVF clinics serving patients with hereditary disease risk.
• Preimplantation Genetic Testing for Chromosomal Rearrangements (PGT-SR) Testing designed to identify embryos with chromosomal structural rearrangements such as translocations or inversions, helping couples with balanced chromosomal arrangements reduce the risk of miscarriage or affected offspring. Sold to IVF clinics.
• Genetic Counseling
• Deep Learning-Enhanced Embryo Selection AI-powered embryo selection service using deep learning algorithms to analyze genetic data from embryo cells and predict embryos with optimal genetic profiles, intended to increase chances of successful pregnancy. Approved for clinical trials; not yet a commercially launched routine service.

Quantifiable outcome

• Embryos with aneuploidy are more likely to result in failed transfer or miscarriage; PGT-A results may increase the chances of a successful pregnancy through informed selection

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Natera: Natera operates the Empower PGT-A test and a broad reproductive and oncology genetic-testing portfolio; it is a primary direct competitor in preimplantation genetic testing and has far larger scale and commercial reach than Gattaca.
• CooperGenomics: CooperGenomics (part of CooperSurgical) provides PGT-A, PGT-M, PGT-SR and genetic counseling to IVF clinics, directly overlapping Gattaca's bundled testing-plus-counseling offering.
• Igenomix: Igenomix (now part of VitroLife) is a leading global provider of reproductive genetics services including PGT-A, PGT-M, and PGT-SR, competing directly with Gattaca's core menu for IVF clinic partnerships and patient samples.
• Sema4 (now part of GeneDx): Sema4 (acquired by GeneDx) operated reproductive and hereditary genetic-testing services overlapping with Gattaca's PGT menu, particularly carrier screening and embryo-related testing.
• Reprogenetics: Reprogenetics is a clinical lab specializing in PGT and reproductive genetics with PGT-A, PGT-M, and PGT-SR offerings, serving the same IVF clinic and patient segments as Gattaca.
• Genesis Genetics: Genesis Genetics is a PGT-focused clinical laboratory offering PGT-A, PGT-M, and PGT-SR, directly competing with Gattaca for IVF clinic volume in the U.S. reproductive-genetics market.
• Genomic Prediction: Genomic Prediction offers PGT-A and PGT-P (polygenic) services using next-generation sequencing, and like Gattaca emphasizes advanced molecular technology applied to embryo selection in IVF clinics.

Broad incumbents

• Myriad Genetics: Myriad Genetics is an established genetic-testing company with hereditary cancer, prenatal, and carrier screening products, representing a broad-incumbent alternative for reproductive genetics customers.
• Labcorp: Labcorp operates one of the largest U.S. clinical lab networks with reproductive and prenatal genetic testing capabilities, acting as a broad incumbent alternative to Gattaca for clinics seeking a single large reference lab.
• Vitrolife: Vitrolife supplies IVF consumables and now owns Igenomix, giving it both lab-supply and PGT-service exposure; it is a strategic partner of Gattaca but also a broader competitor in reproductive-genetics services and IVF workflow products.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/GattacaGenomics
• Facebookfacebook.com/GattacaGenomics
• LinkedInlinkedin.com/company/gattacagenomics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gattaca Genomics